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EMEA was the ﬁrst regulatory authority which established
guidelines for Similar Biological Products (SBPs) approval [1e3] after
the expiry of the ﬁrst generation biopharmaceutical patents. These
guidelines are encouraging for manufacturers for the development
of SBPs to produce cost saving analogs. India has advantages such as
low cost manufacturing and availability of workforce with high skills
at relatively reasonable remuneration to establish manufacturing
facility with adequate investment and to conform with the EU
regulatory requirements. India can also become a good outsourcing
destination for the manufacture of SBPs. Currently, India ranks third
among the list of countries which US ﬁrms [34%] consider as
a possible destination for outsourcing preceded by Singapore [36.5%]
and Ireland [35.4%] [4]. This review focuses on the status of innovator
biotherapeutics in India, key steps involved in their approvals in
India and other important aspects of biotherapeutics.
2. Overview of Indian guidelines and regulatory compliance
in India
In 1989, the Indian Government published “Rules for the
Manufacture/Use/Import/Export and Storage of Hazardous Micro-
organisms, Genetically Engineered Organisms or Cells” through the
Notiﬁcation No. G.S.R.1037(E), dated 5th December, 1989 under the
provisions of Environment (Protection) Act, 1986 through the
Ministry of Environment and Forests. These rules, referred to as
‘Rules 1989’ are implemented by the Ministry of Environment and
Forests and the Department of Biotechnology (DBT) of Ministry ofll rights reserved. The World HealthScience and Technology, Government of India, who have also issued
a guideline in 1999 “Generating pre-clinical and clinical data for r-
DNA based Vaccines, Diagnostics and other biologicals”. From time
to time, DBT also devises proformas for submission of applications
to various competent authorities in India for speciﬁc approvals [5].
Based on these guidelines, the regulatory process is rather
complex. An applicant needs to apply ﬁrst to the regulatory body,
Review Committee on Genetic Manipulations (RCGM) of the
Department of Biotechnology [6] for approval for SBPs. RCGMmoni-
tors the safety related aspects of ongoing recombinant DNA projects
and activities involving genetically engineered organisms/hazardous
microorganisms to ensure that adequate precautions and contain-
ment conditions are complied with as per the Guidelines and Stan-
dard Operating Procedures issued by DBT [5]. DBT alsomaintains the
Indian Genetically Modiﬁed Organism (GMO) Research Information
Systemwhich is aweb based database on activities involving the use
of GMOs and products thereof in India. The primary purpose of this
website is to make available objective and realistic scientiﬁc infor-
mation relating to GMOs and products thereof under research and
commercial use to all stakeholders including scientists, regulators,
industry and the public in general. It also promotes national and
international collaborations in biotech research [6].
Subsequently, the data will be submitted to Drugs Controller
General (India) [DCG(I)] to get approval for clinical trials and ﬁnal
commercial licensure (Table 1). After the DCG(I) approves the
product, the facility is subjected to joint inspection by the Central
and State Drug Control Administration and the manufacturing
license is issued by the Central Licensing Approval Authority [7].
3. Biotherapeutics in India
In 2010, the Department of Pharmaceuticals of the Government
of India set the nation’s biopharmaceutical industry a lofty goal: toOrganization has granted the Publisher permission for the reproduction of this article.
Table 1
Recombinant therapeutics approved for marketing in India.
Molecules Therapeutic
applications
Manufacturers
Insulin Diabetes Biocon, Cadila, Lupin,
Nicholas Piramal,
Wockhardt, Abott,
Eli Lilly, Novo Nordisk.
Erythropoietin Treatment
of anemia
Biocon, Emcure, Intas,
Shantha Biotec,
Wockhardt, Zydus
Biogen, Ranbaxy,
LG chemicals, Hindustan
Antibiotics, Nicholas
Piramal.
Hepatitis B vaccine
(recombinant surface
antigen based)
Immunization
against
Hepatitis B
Bharat Biotech, Biological
E Limited, Merind, Sun,
Shantha Biotec, Panacea
Biotech, Serum
International, Bharat
Serum, LG chemicals,
Zydus Cadila,
GlaxoSmithKline.
Human growth
hormone
Deﬁciency of
growth hormone
in children
Serum International,
Ranbaxy, Novo Nordisk,
Eli Lilly, LG Chemicals,
Elvina Lab.
Interleukins
 Interleukin-2
 Interleukin-11
Renal cell
carcinoma;
Thrombocytopenia
Ambala Sarabhai
Enterprises.
Wyeth
Granulocyte colony
stimulating factor
Chemotherapy
induced
neutropenia
Rhone Poulenc, Fulford,
Dr Reddy’s Lab, Cadila
Health Care, Emcure
Biotech
Granulocyte
macrophage colony
stimulating factor
Chemotherapy
induced
neutropenia
United Biotech, Fulford,
Roche Scientiﬁc Company.
Interferon alpha2 Chronic myeloid
leukemia
Shantha Biotec, Kee
Pharma, Fulford,
Cadila, Lupin Labs,
LG Chemicals,
Nicholas Piramal.
Interferon beta Chronic myeloid
leukemia, Hepatitis
B and Hepatitis C
Serum International;
Fulford, Nicholas
Piramal.
Interferon gamma Chronic
granulomatous
disease and severe
malignant
osteopetrosis
Nicholas Piramal
Streptokinase Acute myocardial
infarction
Cadila-H, Lupin, Sanoﬁ
Aventis, United Biotech,
Human Pharmacia.
Tissue plasminogen
activator
Acute myocardial
infarction
Emcure, German
Remedies,
Zydus Cadila.
Factor VIII Haemophilia
type A
Hemophilia Federation
of India
Follicle stimulating
hormone
Reproductive
disorders
Win Medicare, Infar,
Serum International,
Chandra Bhagat.
Parathyroid
hormone
1e34
Osteoporosis Eli Lilly.
Activated
protein C
Severe sepsis Eli Lilly.
Platelet derived
growth factor
(PDGF)
Bone marrow
induction and
osteoblasts
proliferation
Virchow, Systagenix.
Epidermal growth
factor (EGF)
Mitogenesis
and organ
morphogenesis
Bharat Biotech.
Factor VIIa Haemorrhages,
congenital or
acquired hemophilia
Nova Nordisk
Source: IGMORIS [Indian GMO Research Information System]; Department of
Biotechnology, Government of India.
P.V.C. Babu / Biologicals 39 (2011) 300e303 301become a leading global producer of affordable biotherapeutic
products by 2020 [8]. The Indian biologicals market consists
primarily of vaccines, biotherapeutic drugs, animal biologicals, and
diagnostics [9]. About 20 Indian companies are already producing
the biotherapeutics: Dr. Reddy’s Laboratories, Ranbaxy, Biocon,
Shanta Biotech, Reliance Life Sciences, Panacea Biotech, Bharat
Biotech and Intas Biopharmaceuticals are among those lead the
way [8]. Several other companies are also interested in pursuing
the development of SBPs (Table 2). Around 50 biotherapeutics
have already hit the Indian market at 85% lower prices that are
affordable to the masses in India. The Indian sales for Erythro-
poietin rose to $22 million, GCSF to $11 million, Interferon to $22
million and Streptokinase to $15 million in the ﬁnancial year
2009e2010 [8].
The domestic market for biotherapeutics in India is limited by
low levels of health insurance, which has resulted in poor access to
biologic drugs; however, given the high level of branded-generic
loyalty of the emerging middle class, this could act as a driver
for uptake of these products. Due to the fact that many non-
innovator biotherapeutics are already available in India and
often are approved as new drugs, it is difﬁcult to quantify their
sales in the emerging markets. Nevertheless, Indian biotechnology
industry revenues touched $150 billion, despite the global
downturn in 2009 and slow recovery in 2010. The industry has
grown consistently in double digits over the last decade with
average revenue growth ﬁgures greater than 20%. It is estimated to
reach a turnover of around $450 billion by 2015 which would
require it to grow at about 30% year on year [10]. The developedTable 2
Organizations working with non-innovator biotherapeutics or SBP.
Biopharmaceutical industries
Abexome Biosciences Pvt. Ltd
Actis Biologics, Mumbai
Advinus Therapeutics
AstraZeneca India Pvt. Ltd, Bangalore
Aumgene Biosciences Pvt. Ltd
Avesthagen Pvt. Ltd
Bharat Biotech International Ltd
Bharat Serums and Vaccines Ltd, Mumbai
Bhat Bio-Tech India (P) Ltd, Bangalore
Biocon India Ltd, Bangalore
Biological E. Ltd, Hyderabad
Cadila Health Care Ltd, Ahmedabad
Cadila Pharmaceuticals Ltd, Ahmedabad
Claris Life Sciences, Ahmedabad
Clinigene International Ltd, Bangalore
Connexios Life Sciences, Bangalore
Dr. Reddy’s Laboratories Ltd, Hyderabad
Fermenta Biotech Ltd, Thane (W)
Gangagen Biotechnologies Pvt Ltd, Bangalore
Gennova Biopharmaceuticals Ltd, Pune
Human Biologicals Institute Hyderabad
Indian Immunologicals Ltd, Hyderabad
Lupin Laboratories Ltd, Mumbai
Panacea Biotech Ltd, New Delhi
Ranbaxy Laboratories Ltd, Gurgaon
Reliance Life Sciences Pvt. Ltd, Mumbai
Serum Institute of India Ltd, Pune
Shantha Biotechnics Ltd, Medchal
Shasun Chemicals and Drugs Ltd, Chennai
Sudarshan Biotech Ltd, Hyderabad
SUN Pharmaceutical Industries Ltd, Mumbai
Syngene International Pvt. Ltd, Bangalore
Transgene Biotek Ltd, Medak
Virchow Biotech Pvt. Ltd, Hyderabad
Wockhardt Ltd, Mumbai
Zenotech Laboratories Ltd, Hyderabad
Source: IGMORIS [Indian GMO Research Information System]; Department of
Biotechnology, Government of India.
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complex and expensive clinical trials and registration process.
However, licensing agreements with multinational companies,
such as the recent deal between Biocon and Pﬁzer, can facilitate
access to these markets [11].
4. Expectations e Indian perspective
As different manufacturers are involved in SBPs segment, it
would be highly useful if the Indian NRA were to assess the risk
beneﬁt ratios of SBPs and issue product speciﬁc guidelines as in the
EU. In addition, a unique system of identiﬁcation is also needed for
the biosimilars. Manufacturing of SBPs poses different challenges
but also affords important opportunities. The challenges include
skill development, government funding support, funding from
investors and ﬁnancial institutions, knowledge of patenting and
intellectual property rights, public private partnerships with
national and international universities and/or organizations, for
becoming a competitor in the SBPs market.
Several educational institutions and universities are available
in India, which offer courses related to biotechnology, but the
gap between the industrial needs and the workforce skill
development in these institutes and universities needs to be
narrowed down. The best example being, The Government of
Karnataka, one of the Southern States in India, along with Kar-
nataka Biotechnology and Information Technology Services and
Association of Biotech Led Enterprises, organized a workshop on
the Karnataka Biotech Policy II in Bangalore on February 2011.
This workshop provided a platform for industrialists, entrepre-
neurs, academicians and Government ofﬁcials to engage in an
open house discussion about the ways and means to improve
education, investment and, research and development in the
ﬁeld of biotechnology in Karnataka [12].
Manufacture of SBPs is complex, the major challenge being
the demonstration of similarity with the reference product
[13,14]. In India, only a few laboratories or institutes are available
for physicoechemical characterization. For these characteriza-
tions, most of the manufacturers generally depend on US and
Europe for service, especially for protein structural analysis.
Indian NRA should initiate the establishment of recognized
institute trainers/consultants to build a strong analytical support
for the manufacturers and also establishment of acceptance
criteria for the SBPs.
Non-clinical toxicity studies are done as per “Schedule YeDrugs
and Cosmetics (IInd AMENDMENT) Rules, 2005” [15] for the bio-
therapeutics which is applicable to SBPs. Though demonstration of
biosimilarity is performed by physicoechemical and bioechemical
characterization, it is mandatory that the product is assessed for
non-clinical toxicity studies as per Schedule Y. There should be
clarity for the use of animal species appropriate for the speciﬁc SBPs
which if suitable, can also alternate to the non-clinical study
methods. As limited facilities are available to conduct the study in
dogs and primates and in viewof the potential increased production
of various biotherapeutics, the NRA should activate the National
Animal Resource Facility in collaboration with Indian Council of
Medical Research [ICMR] and promote additional laboratories in
private sector to conduct non-clinical toxicity studies in dogs and
primates.
Clinical studies are done as per “Schedule Y e Drugs and
Cosmetics (IInd AMENDMENT) Rules, 2005” [15]. Most critical part
in SBPs evaluation is the safety and efﬁcacy by clinical compara-
bility with the reference product. The study should begin with
pharmacokinetic study (PK) followed by pharmacodynamic studies
(PD), efﬁcacy study, immunogenicity and with a pharmacovigilance
study (PMS). All these studies involve clinicians, hospitals, publichealth departments and public. NRA should have themechanism to
monitor clinical studies for their proper conduct. Presence of traces
of impurities, structural modiﬁcations or degradants during
manufacturing and at the time of storage may increase immuno-
genicity. Understanding the antibody interaction and antibody
testing is critical for immunogenicity studies. The most critical
safety concern in SBPs is immunogenicity and hence the present
methods for detection of immunogenicity should be improved
upon [16,17]. PMS should have complete follow up of the, pre- and
post- comparative plan, identifying the missing and potential risks.
All these factors (PK, PD, immunogenicity, PMS) are critical in
assessing the efﬁcacy and safety of the SBP.
5. Conclusion
Indian manufacturers are well positioned to capitalize on the
future growth of the biotech market both domestically and interna-
tionally.Anencouragingdevelopment for the Indianmanufacturers is
that the ‘Guidance for Industry’ was issued in 2009 by the Central
Drugs Standard Control Organization, Ministry of Health, Govern-
mentof India.However, it is very important tomention that the issues
relating to SBPs is a recentdevelopment and India needs toworkwith
regulatory authorities of other countries, manufacturers, clinicians,
scientists and the public to ﬁnalize the policies and procedures for
implementingappropriatemeasures to complywithWHOguidelines
and ensure the delivery of safe and effective products.
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